neorustmicin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

neorustmicin A: active against wheat stem rust fungus; isolated from Micromonospora chalcea 1302-AV2; MF C21-H32-O5; structure given in first source; has also been isolated from Streptomyces galbus [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	6438862
CHEMBL ID	284267
MeSH ID	M0137829

Synonyms (5)

Synonym
100157-26-4
neorustmicin a
CHEMBL284267
(3r,5s,7e,9s,12e,14s)-14-ethyl-5-hydroxy-5-(hydroxymethyl)-3,7,9,13-tetramethyl-11-methylidene-1-oxacyclotetradeca-7,12-diene-2,4-dione
erythronolide a, 6,7,10,11,12,20-hexadehydro-9-deoxo-3,5,6,11,12-pentadeoxy-4,17-dihydroxy-3-oxo-

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay ID	Title	Year	Journal	Article
AID39699	In vitro antifungal activity against Aspergillus fumigatus TIMM1776; activity expressed as minimum inhibitory concentration	2004	Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1	Novel galbonolide derivatives as IPC synthase inhibitors: design, synthesis and in vitro antifungal activities.
AID45478	In vitro antifungal activity against Candida albicans ATCC 90028; activity expressed as minimum inhibitory concentration	2004	Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1	Novel galbonolide derivatives as IPC synthase inhibitors: design, synthesis and in vitro antifungal activities.
AID202873	In vitro antifungal activity against Saccharomyces cerevisiae Y9; activity expressed as minimum inhibitory concentration	2004	Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1	Novel galbonolide derivatives as IPC synthase inhibitors: design, synthesis and in vitro antifungal activities.
AID55035	In vitro antifungal activity against Cryptococcus neoformans ATCC 9011; activity expressed as minimum inhibitory concentration	2004	Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1	Novel galbonolide derivatives as IPC synthase inhibitors: design, synthesis and in vitro antifungal activities.
AID54870	In vitro antifungal activity against Cryptococcus neoformans ATCC 9011	2004	Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1	Novel galbonolide derivatives as IPC synthase inhibitors: design, synthesis and in vitro antifungal activities.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	3 (37.50)	18.7374
1990's	1 (12.50)	18.2507
2000's	3 (37.50)	29.6817
2010's	1 (12.50)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.54 (24.57)
Research Supply Index	2.20 (2.92)
Research Growth Index	4.73 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.54)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	8 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	2.02	1	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
allyl alcohol allyl alcohol: structure. allylic alcohol : An alcohol where the hydroxy group is attached to a saturated carbon atom adjacent to a double bond (R groups may be H, organyl, etc.).. allyl alcohol : A propenol in which the C=C bond connects C-2 and C-3. It is has been found in garlic (Allium sativum). Formerly used as a herbicide for the control of various grass and weed seeds.	2.03	1	primary allylic alcohol; propenol	antibacterial agent; fungicide; herbicide; insecticide; plant metabolite
phenyl acetate phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.	2.03	1	benzenes; phenyl acetates
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	2.02	1	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
rustmicin rustmicin: active against wheat stem rust fungus; isolated from Streptomyces galbus Micromonospora narashinoensis 980-MC1; MF C21-H32-O6; structure given in first source; also isolated from Streptomyces galbus	2.9	4

chemdatabank.com